Trial Profile

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HuMax IL8 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary) ; Celecoxib
Indications Adenocarcinoma; Colon cancer
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Acronyms NICHE; NICHE-2; NICHE-3

01 Nov 2024 Results (n=59) assessing high efficacy and favorable toxicity profile of anti-PD-1 plus anti-LAG-3, published in the Nature Medicine.
17 Sep 2024 Study NICHE-3 is fully accrued according to the results presented at the 49th European Society for Medical Oncology Congress.
16 Apr 2024 The study was amended in Nov 2022 to add cohort 5 and 6, both in which patients will receive nivolumab plus relatlimab (anti-LA G3).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com